Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After Randomization, The Rate Of Conversion To AVR Was 47.2%
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences reported results from the EARLY TAVR trial, indicating that 26.2% of patients in the clinical surveillance arm converted to AVR within the first 6 months, with a 47.2% conversion rate in the 12-month follow-up period.
October 28, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences' EARLY TAVR trial results show high conversion rates to AVR, which may impact the company's product adoption and stock price.
The high conversion rates to AVR in the EARLY TAVR trial suggest strong demand and potential for increased adoption of Edwards Lifesciences' products. This could positively influence investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100